Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan
| Autor: | Masayuki Kubo, Masaki Hayakawa, Masanori Matsumoto, Kazuya Sakai, Yumi Yoshii |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Thrombotic thrombocytopenic purpura ADAMTS13 Protein Gastroenterology Disease-Free Survival Japan Refractory Recurrence immune system diseases hemic and lymphatic diseases Internal medicine Secondary Prevention medicine Humans Aged Autoantibodies Retrospective Studies Purpura Thrombocytopenic Idiopathic Hematology business.industry Incidence (epidemiology) Autoantibody Retrospective cohort study Off-Label Use Middle Aged medicine.disease ADAMTS13 Treatment Outcome Female Rituximab business Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Hematology. 112:764-772 |
| ISSN: | 1865-3774 0925-5710 |
| Popis: | Immune thrombotic thrombocytopenic purpura (iTTP) is caused by ADAMTS13 deficiency due to anti-ADAMTS13 autoantibodies. Rituximab, an anti-CD20 monoclonal antibody, is often used to suppress these autoantibodies. This retrospective study, conducted in an iTTP cohort in Japan, evaluated the long-term efficacy of rituximab as off-label treatment for refractory or relapsed cases. A total of 252 iTTP patients with severe ADAMTS13 deficiency ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink